Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The results of the large cardiovascular event-driven safety trial comparing tirzepatide with dulaglutide in 12,500 participants in the SURPASS-CVOT study are expected in 2024 (78)
Limon-Pacheco JH, Gonsebatt ME
Appetite suppression: This part has officially kicked in
Pharmaceutical companies are actively expanding their presence in the Asia Pacific by pursuing regulatory approvals, launching clinical trials, and forming partnerships with regional healthcare organizations
doi: 10.1089/bio.2019.0037, 9
eccCDSs variants carried on eccDNA can diverge from their chromosomal templates without compromising core genome integrity, allowing even individual cells to explore new allelic or regulatory states
